Enhanced Molecular Response in Myeloproliferative Neoplasms with Complete JAK2V617F Inhibition

被引：0

作者：

Celik, Hamza ^{[1
]}

Challen, Grant A. ^{[2
,3
]}

机构：

[1] Incyte Res Inst, Wilmington, DE USA

[2] Washington Univ, Sch Med, Div Oncol, Dept Med, St Louis, MO 63110 USA

[3] Washington Univ, Sch Med, 660 Euclid Ave, St Louis, MO 63110 USA

来源：

CANCER DISCOVERY | 2024年 / 14卷 / 05期

关键词：

MUTATION ORDER; EFFICACY;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Dunbar, Bowman, and colleagues present here a novel genetic mouse model with inducible and reversible expression of the JAK2(V617F) mutation in the endogenous locus. Results from this study clearly demonstrate an absolute requirement for myeloproliferative neoplasm-initiating cells for this mutation in their survival and imply that more efficacious inhibitors could be curative for these patients even in the setting of additional cooperating mutations.

引用

页码：701 / 703

页数：3

共 17 条

[1] Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Dunbar, Andrew J.
Bowman, Robert L.
Park, Young C.
O'Connor, Kavi
Izzo, Franco
Myers, Robert M.
Karzai, Abdul
Zaroogian, Zachary
Kim, Won Jun
Fernandez-Maestre, Ines
Waarts, Michael R.
Nazir, Abbas
Xiao, Wenbin
Codilupi, Tamara
Brodsky, Max
Farina, Mirko
Cai, Louise
Cai, Sheng F.
Wang, Benjamin
An, Wenbin
Yang, Julie L.
Mowla, Shoron
Eisman, Shira E.
Somasundara, Amritha Varshini Hanasoge
Glass, Jacob L.
Mishra, Tanmay
Houston, Remie
Guzzardi, Emily
Benitez, Anthony R. Martinez
Viny, Aaron D.
Koche, Richard P.
Meyer, Sara C.
Landau, Dan A.
Levine, Ross L.
CANCER DISCOVERY, 2024, 14 (05) : 737 - 751
[2] Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms
Deshpande, A.
Reddy, M. M.
Schade, G. O. M.
Ray, A.
Chowdary, T. K.
Griffin, J. D.
Sattler, M.
LEUKEMIA, 2012, 26 (04) : 708 - 715
[3] The JAK2V617F mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden
Orbell, Lai Yee
Abutheraa, Nouf
Duncombe, Andrew S.
Mcmullin, Mary Frances
Mesa, Ruben
Mcshane, Charlene M.
James, Glen
Anderson, Lesley A.
EJHAEM, 2023, 4 (04): : 1071 - 1080
[4] JAK2V617F molecular remission in a primary myelofibrosis patient treated with ruxolitinib
Koehler, Anne
Hubert, Karolin
Lange, Thoralf
Siebolts, Udo
Wickenhauser, Claudia
Gopalakrishna, Prashanth
Niederwieser, Dietger
Monecke, Astrid
Al-Ali, Haifa Kathrin
ANNALS OF HEMATOLOGY, 2015, 94 (11) : 1929 - 1930
[5] Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells
Machado-Neto, Joao Agostinho
Coelho-Silva, Juan Luiz
de Souza Santos, Fabio Pires
Scheucher, Priscila Santos
Campregher, Paulo Vidal
Hamerschlak, Nelson
Rego, Eduardo Magalhaes
Traina, Fabiola
INVESTIGATIONAL NEW DRUGS, 2020, 38 (03) : 733 - 745
[6] Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms
Hu, Min
Xu, Chengbo
Yang, Chao
Zuo, Hongli
Chen, Chengjuan
Zhang, Dan
Shi, Gaona
Wang, Wenjie
Shi, Jiangong
Zhang, Tiantai
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
[7] Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms
Zhao, Baobing
Mei, Yang
Cao, Lan
Zhang, Jingxin
Sumagin, Ronen
Yang, Jing
Gao, Juehua
Schipma, Matthew J.
Wang, Yanfeng
Thorsheim, Chelsea
Zhao, Liang
Stalker, Timothy
Stein, Brady
Wen, Qiang Jeremy
Crispino, John D.
Abrams, Charles S.
Ji, Peng
JOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (01) : 125 - 140
[8] R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm
Shide, Kotaro
Kameda, Takuro
Markovtsov, Vadim
Shimoda, Haruko K.
Tonkin, Elizabeth
Fang, Shuling
Liu, Chian
Gelman, Marina
Lang, Wayne
Romero, Jason
McLaughlin, John
Bhamidipati, Somasekhar
Clough, Jeffrey
Low, Caroline
Reitsma, Andrea
Siu, Stacey
Pine, Polly
Park, Gary
Torneros, Allan
Duan, Matt
Singh, Rajinder
Payan, Donald G.
Matsunaga, Takuya
Hitoshi, Yasumichi
Shimoda, Kazuya
BLOOD, 2011, 117 (25) : 6866 - 6875
[9] Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms - long term follow-up of a regional case series
Greenfield, Graeme
McMullin, Mary Frances
THROMBOSIS JOURNAL, 2018, 16
[10] Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib
Luque Paz, Damien
Ianotto, Jean-Christophe
Chauveau, Aurelie
Guibourg, Briac
Lecucq, Lydie
Lippert, Eric
Ugo, Valerie
ANNALS OF HEMATOLOGY, 2016, 95 (02) : 349 - 350

← 1 2 →